2024
AGA Clinical Practice Update on Integrating Potassium-Competitive Acid Blockers Into Clinical Practice: Expert Review
Patel A, Laine L, Moayyedi P, Wu J. AGA Clinical Practice Update on Integrating Potassium-Competitive Acid Blockers Into Clinical Practice: Expert Review. Gastroenterology 2024, 167: 1228-1238. PMID: 39269391, DOI: 10.1053/j.gastro.2024.06.038.Peer-Reviewed Original ResearchPotassium-competitive acid blockerClinical Practice UpdateFirst-line therapyProton pump inhibitorsTwice-daily proton pump inhibitorBest Practice Advice statementsPractice advice statementsPeptic ulcer diseaseErosive esophagitisHeartburn symptomsAmerican Gastroenterological Association (AGA) Institute Clinical Practice UpdateClinical superiorityDouble-dose PPIsDouble-dose proton pump inhibitorsProphylaxis of peptic ulcer diseaseReflux diseaseStandard-dose PPIUlcer diseaseExpert reviewStandard procedures of GastroenterologyHigh-risk stigmataAcid inhibitionOn-demand therapyMaintenance of healingBleeding gastroduodenal ulcersComparison of LA Grades of Erosive Esophagitis Scored by Local Investigators vs Central Adjudicators in a Clinical Trial
Spechler S, Laine L, DeVault K, Nabulsi A, Hunt B, Katz P. Comparison of LA Grades of Erosive Esophagitis Scored by Local Investigators vs Central Adjudicators in a Clinical Trial. Clinical Gastroenterology And Hepatology 2024 PMID: 38777170, DOI: 10.1016/j.cgh.2024.05.007.Peer-Reviewed Original ResearchVonoprazan is Efficacious for Treatment of Heartburn in Non-erosive Reflux Disease: A Randomized Trial
Laine L, Spechler S, Yadlapati R, Schnoll-Sussman F, Smith N, Leifke E, Harris T, Hunt B, Fass R, Katz P. Vonoprazan is Efficacious for Treatment of Heartburn in Non-erosive Reflux Disease: A Randomized Trial. Clinical Gastroenterology And Hepatology 2024, 22: 2211-2220.e10. PMID: 38750866, DOI: 10.1016/j.cgh.2024.05.004.Peer-Reviewed Original ResearchNon-erosive reflux diseaseHeartburn-free daysErosive esophagitisReflux diseaseRandomized trialsActive-treatment extensionRandomized to placeboPotassium-competitive acid blockerPlacebo-controlled periodDays of therapyPercentage of subjectsPrimary endpointPercentage of daysHeartburn symptomsPlaceboVonoprazanAcid blockerNighttime heartburnDay 1Randomized subjectsDocumented efficacyStudy armsDay 2Adult subjectsExtension period
2022
Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial
Laine L, DeVault K, Katz P, Mitev S, Lowe J, Hunt B, Spechler S. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial. Gastroenterology 2022, 164: 61-71. PMID: 36228734, DOI: 10.1053/j.gastro.2022.09.041.Peer-Reviewed Original ResearchConceptsMaintenance of healingProton pump inhibitorsErosive esophagitisSecondary analysisD esophagitisPrimary analysisEnd pointPotassium-competitive acid blocker vonoprazanHeartburn-free daysSevere erosive esophagitisMainstay of treatmentPrimary end pointSecondary end pointsPotent acid inhibitionPPI lansoprazolePump inhibitorsEsophagitisNoninferiority comparisonVonoprazanWeek 2Healing phaseAbstractTextPatientsLansoprazoleSuperiority analysis
2014
Causes of Bleeding and Outcomes in Patients Hospitalized With Upper Gastrointestinal Bleeding
Kim JJ, Sheibani S, Park S, Buxbaum J, Laine L. Causes of Bleeding and Outcomes in Patients Hospitalized With Upper Gastrointestinal Bleeding. Journal Of Clinical Gastroenterology 2014, 48: 113-118. PMID: 23685847, DOI: 10.1097/mcg.0b013e318297fb40.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overEndoscopy, GastrointestinalEsophageal and Gastric VaricesEsophagitisFemaleGastrointestinal HemorrhageHematemesisHospital MortalityHospitalizationHumansLength of StayMaleMedicaidMedicareMelenaMiddle AgedPeptic UlcerPeptic Ulcer HemorrhageRetreatmentRetrospective StudiesUnited StatesConceptsUpper gastrointestinal bleedingGastrointestinal bleedingCommon causeOutcomes of UGIBVariceal upper gastrointestinal bleedingNonvariceal upper gastrointestinal bleedingCause of bleedingRisk of deathLower socioeconomic patientsUrban US hospitalsErosive esophagitisInpatient mortalityRepeat endoscopyUpper endoscopyConsecutive patientsClinical outcomesPeptic ulcerMean ageMedical CenterUrban hospitalPatientsUS hospitalsMultivariate analysisHematemesisEndoscopy
2009
Endoscopy of the esophagus in gastroesophageal reflux disease: are we losing sight of symptoms? Another perspective
Sharma P, Chey W, Hunt R, Laine L, Malfertheiner P, Wani S. Endoscopy of the esophagus in gastroesophageal reflux disease: are we losing sight of symptoms? Another perspective. Diseases Of The Esophagus 2009, 22: 461-466. PMID: 19191851, DOI: 10.1111/j.1442-2050.2008.00934.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsGastroesophageal reflux diseaseGERD-like symptomsSuppressive therapyReflux diseaseAcid suppressive therapyErosive reflux diseaseProspective multicenter studyCommon chronic disorderPrimary care physiciansPrimary care settingSymptom-based classificationSymptom-based diagnosisHuge economic burdenInternational Consensus GroupErosive esophagitisGERD patientsTroublesome symptomsEmpiric trialPartial responseComplete responseCare physiciansImpaired qualityMulticenter studyBarrett's esophagusChronic disorders
2004
Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: A double-blind trial
Laine L, Maller ES, Yu C, Quan H, Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: A double-blind trial. Gastroenterology 2004, 127: 395-402. PMID: 15300570, DOI: 10.1053/j.gastro.2004.05.001.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-Inflammatory Agents, Non-SteroidalAspirinCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDouble-Blind MethodDrug Therapy, CombinationFemaleGastric MucosaHumansIbuprofenIncidenceIsoenzymesLactonesMaleMembrane ProteinsMiddle AgedOsteoarthritisProstaglandin-Endoperoxide SynthasesRisk FactorsStomach UlcerSulfonesTablets, Enteric-CoatedConceptsNonselective nonsteroidal anti-inflammatory drugsLow-dose aspirinCOX-2 selective inhibitorsDouble-blind trialUlcer incidenceNonselective NSAIDsLow-dose enteric-coated aspirinLow-dose aspirin usersCyclooxygenase-2 selective inhibitorSelective inhibitorNonsteroidal anti-inflammatory drugsEnteric-coated aspirinGastrointestinal mucosal injuryNumber of erosionsRisk of ulcerAnti-inflammatory drugsCOX-2 selective inhibitionYears of ageBaseline endoscopyAspirin usersDose aspirinErosive esophagitisCumulative incidenceMucosal injuryRepeat endoscopy
2002
Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies
Sugg J, Laine L. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. The American Journal Of Gastroenterology 2002, 97: 2992. PMID: 12492181, DOI: 10.1111/j.1572-0241.2002.07116.x.Peer-Reviewed Original ResearchConceptsPersistent H. pyloriErosive esophagitisGERD symptomsH. pyloriSymptomatic GERDPersistent infectionDouble-blind prospective studyDouble-blind prospective trialGastroesophageal reflux disease symptomsCompletion of therapyDuodenal ulcer diseaseGastroesophageal reflux diseaseHelicobacter pylori eradicationHelicobacter pylori therapyWorsening of symptomsEnd of therapyRapid urease testBlind prospective studyPylori eradicationPylori therapyReflux diseaseRegurgitation scoreProspective trialDuodenal ulcerUlcer disease